MorphoSys

Morphosys to buy Constellation in $1.7B deal, aided by unusual funding
BioPharma Dive
Wed, 06/2/21 - 12:10 pm
MorphoSys
M&A
Constellation Pharmaceuticals
OptumRx's 3 recently approved drugs to watch
Beckers Hospital Review
Tue, 09/22/20 - 10:15 pm
FDA
Kite Pharma
Tecartus
Novartis
Kesimpta
MorphoSys
Monjuvi
OptumRx
FDA approves MorphoSys, Incyte’s drug for vulnerable lymphoma population
MedCity News
Mon, 08/3/20 - 10:14 am
FDA
Monjuvi
CAR-T
MorphoSys
Incyte
diffuse large B-cell lymphoma
Morphosys’ off-the-shelf rival to CAR-T approaches finish line with a speedy review
Endpoints
Mon, 03/2/20 - 09:37 am
MorphoSys
Gilead Sciences
Novartis
CAR-T
tafasitamab
DLBCL
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug
Xconomy
Mon, 01/13/20 - 11:51 pm
Incyte
MorphoSys
lymphoma
tafasitamab
Trials of Novartis' Dupixent rival bet scrapped by MorphoSys, Galapagos
Fierce Biotech
Tue, 10/29/19 - 09:57 am
MorphoSys
Galapagos
Novartis
MOR106
atopic dermatitis
Dupixent
Sanofi
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
Morphosys to take on CAR-Ts in NHL with promising antibody
Pharmaforum
Mon, 05/20/19 - 11:02 pm
MorphoSys
Celgene
Revlimid
non-Hodgkin lymphoma
clinical trials
tafasitamab
Better than CAR-T? Already prepping for a US launch, MorphoSys posts stellar DLBCL data to field against Novartis, Gilead
Endpoints
Fri, 05/17/19 - 01:03 pm
CAR-T
MorphoSys
Novartis
Gilead Sciences
tafasitamab
DLBCL
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
CP Wire
Fri, 02/1/19 - 09:44 am
MorphoSys
Janssen
Genmab
daratumumab
patents
MorphoSys Settles Patent Lawsuit with Janssen and Genmab
Fri, 02/1/19 - 09:43 am
MorphoSys
Janssen
Genmab
patent lawsuits
patents
Darazalex
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
CP Wire
Mon, 01/28/19 - 11:02 am
MorphoSys
Janssen
Genmab
patents
MorphoSys Patents Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
Mon, 01/28/19 - 10:10 am
MorphoSys
Janssen
Genmab
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
Mon, 12/17/18 - 09:44 am
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
With no partner, MorphoSys drops MOR202 in myeloma
Biopharma Dive
Fri, 08/3/18 - 10:53 pm
MorphoSys
earnings
anti-CD3 antibody
MOR202
Novartis to Pay as Much as $1 Billion for Rights to Skin Drug
Yahoo/Bloomberg
Thu, 07/19/18 - 09:53 am
Novartis
Galapagos
MorphoSys
MOR106
atopic dermatitis
Johnson & Johnson, looking for its Tremfya niche, starts up new trial program in Crohn's
Fierce Pharma
Wed, 07/11/18 - 11:35 am
JNJ
Tremfya
MorphoSys
Janssen
Crohn's Disease
clinical trials
In knockout IPO offerings, MorphoSys and Surface Oncology haul combined $316M in upsized deals
Endpoints
Fri, 04/20/18 - 09:46 am
IPOs
MorphoSys
Surface Oncology
NASDAQ
Galapagos peaks as AbbVie hype builds, Shorts target Bavarian, MorphoSys makes GPCR play
Fierce Biotech
Fri, 08/7/15 - 10:44 am
Galapagos
AbbVie
Bavarian Nordic
Intec Pharma
MorphoSys
MorphoSys: That Celgene-abandoned cancer drug isn't dead yet
Fierce Biotech
Mon, 04/6/15 - 11:03 am
MorphoSys
Celgene
MOR202

Pages